Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

IDEAYA Biosciences, Inc. IDYA

Healthcare  —  Biotechnology
36.69 (0.05) (0.14%) as of 25 Sep
Market cap
$3.6B
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

IDEAYA Biosciences, Inc. (IDYA) Business Profile

Updated before January 2025

Company Overview

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is a precision medicine oncology company dedicated to the discovery and development of targeted therapeutics for cancer treatment. Founded in 2015 and headquartered in South San Francisco, California, IDEAYA leverages its expertise in synthetic lethality and immuno-oncology to develop innovative therapies. The company was co-founded by Dr. Yujiro S. Hata, who also serves as the President and Chief Executive Officer. Dr. Hata brings extensive experience in oncology drug development, having held leadership roles at companies like Onyx Pharmaceuticals and Enanta Pharmaceuticals. IDEAYA’s leadership team includes seasoned professionals with deep expertise in biotechnology, oncology, and drug development, positioning the company as a leader in precision medicine.

Core Business Segments

IDEAYA focuses on two primary areas of oncology research and development: synthetic lethality and immuno-oncology. These areas form the foundation of its product pipeline and therapeutic strategies.

Synthetic Lethality

Synthetic lethality is a cutting-edge approach to cancer treatment that targets specific genetic vulnerabilities in cancer cells. IDEAYA’s pipeline includes:

  • MAT2A Inhibitors: IDEAYA is developing MAT2A inhibitors for cancers with MTAP gene deletions, which occur in approximately 15% of all cancers. The company’s lead candidate, IDE397, is currently in clinical trials.
  • Pol Theta Inhibitors: These inhibitors target DNA repair mechanisms in tumors with BRCA or other homologous recombination deficiencies (HRD). IDEAYA is collaborating with GSK to advance this program.
  • WRN Inhibitors: Targeting Werner syndrome helicase, a key vulnerability in microsatellite instability-high (MSI-H) cancers.

Immuno-Oncology

IDEAYA is also exploring therapies that enhance the immune system’s ability to fight cancer. Key programs include:

  • Darovasertib (IDE196): A protein kinase C (PKC) inhibitor being developed for genetically defined cancers, including uveal melanoma and other GNAQ/11 mutant cancers.
  • Combination Therapies: IDEAYA is investigating the potential of combining its therapies with immune checkpoint inhibitors to improve patient outcomes.

Business Model

IDEAYA operates as a clinical-stage biotechnology company, focusing on the discovery and development of targeted oncology therapies. The company generates revenue primarily through strategic collaborations and partnerships with larger pharmaceutical companies. For example, its partnership with GSK provides funding for the development of Pol Theta inhibitors, while allowing IDEAYA to retain significant downstream value through milestone payments and royalties.

The company’s business model emphasizes:

  • Collaborative Research: Partnering with leading pharmaceutical companies to co-develop therapies and share resources.
  • Intellectual Property: Building a robust portfolio of patents to protect its proprietary technologies and drug candidates.
  • Clinical Development: Advancing its pipeline through rigorous clinical trials to achieve regulatory approval and commercialization.

Strategic Direction

IDEAYA’s strategic vision is centered on becoming a leader in precision medicine oncology. Key elements of its strategy include:

  • Pipeline Expansion: Continuing to advance its existing programs while identifying new targets in synthetic lethality and immuno-oncology.
  • Global Reach: Expanding its clinical trials to include international sites, thereby increasing access to diverse patient populations.
  • Sustainability Goals: While not explicitly stated, IDEAYA’s focus on targeted therapies aligns with broader healthcare sustainability goals by aiming to reduce the overall burden of cancer treatment.
  • New Product Categories: Exploring opportunities in adjacent areas of oncology, such as tumor microenvironment modulation and next-generation sequencing-based diagnostics.

Competitive Landscape

IDEAYA operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotechs. Key competitors include:

  • AstraZeneca: A leader in synthetic lethality with its PARP inhibitors like Lynparza.
  • GSK: A collaborator and competitor in the development of Pol Theta inhibitors.
  • Mirati Therapeutics: Focused on targeted oncology therapies, including KRAS inhibitors.
  • Blueprint Medicines: Specializes in precision therapies for genetically defined cancers.

IDEAYA differentiates itself through its dual focus on synthetic lethality and immuno-oncology, as well as its strategic partnerships and robust intellectual property portfolio.

Risk Factors

Like any clinical-stage biotechnology company, IDEAYA faces several risks, including:

  • Regulatory Risks: The success of its drug candidates depends on obtaining regulatory approvals, which can be uncertain and time-consuming.
  • Market Dependence: The company’s financial performance is heavily reliant on the success of its lead candidates, such as IDE397 and darovasertib.
  • Supply Chain Disruptions: Dependence on third-party manufacturers and suppliers exposes IDEAYA to potential delays and cost increases.
  • Competitive Pressure: The rapidly evolving oncology landscape means that competitors could develop more effective or less expensive therapies.
  • Financial Risks: As a clinical-stage company, IDEAYA is not yet profitable and relies on external funding to sustain its operations.

Recent Developments

IDEAYA has made significant progress in advancing its pipeline and corporate strategy:

  • Clinical Trials: IDE397 has shown promising results in early-phase trials, leading to its advancement into later-stage studies.
  • Partnerships: The collaboration with GSK has been expanded to include additional targets, reflecting the success of their initial partnership.
  • Corporate Milestones: IDEAYA recently raised additional capital through a public offering, strengthening its financial position.
  • Global Developments: The COVID-19 pandemic initially disrupted clinical trials but also highlighted the importance of innovative healthcare solutions, reinforcing IDEAYA’s mission.

Investment Considerations

Strengths

  • Innovative Pipeline: Focus on synthetic lethality and immuno-oncology positions IDEAYA at the forefront of precision medicine.
  • Strategic Partnerships: Collaborations with industry leaders like GSK provide financial stability and access to additional resources.
  • Experienced Leadership: A seasoned management team with a proven track record in oncology drug development.

Risks

  • Clinical and Regulatory Uncertainty: The success of IDEAYA’s pipeline is not guaranteed.
  • Financial Dependence: The company relies on external funding and partnerships to sustain its operations.
  • Competitive Market: Intense competition from both established players and emerging biotechs.

Conclusion

IDEAYA Biosciences, Inc. is a pioneering company in the field of precision medicine oncology, leveraging cutting-edge science to develop targeted therapies for genetically defined cancers. With a robust pipeline, strategic partnerships, and a focus on innovation, IDEAYA is well-positioned for future growth. However, investors should carefully consider the inherent risks associated with clinical-stage biotechnology companies. As IDEAYA continues to advance its programs and expand its global reach, it remains a compelling player in the oncology space, offering significant potential for long-term value creation.